Intraperitoneal Paricalcitol Treatment for Secondary Hyperparathyroidism in CAPD patient: A Case Report.
- Author:
Ji Min JEON
1
;
Yong Ki PARK
;
Joon Suk OH
;
Sung Min KIM
;
Yong Hun SIN
;
Joong Kyung KIM
Author Information
1. Division of Nephrology, Department of Internal Medicine, Dongrae Bong Seng Hospital, Busan, Korea. bravep2002@yahoo.co.kr
- Publication Type:Case Report
- Keywords:
Paricalcitol;
Intraperitoneal injection;
Secondary hyperparathyroidism;
CAPD
- MeSH:
Administration, Intravenous;
Alkaline Phosphatase;
Calcitriol;
Calcium;
Dialysis;
Ergocalciferols;
Humans;
Hyperparathyroidism, Secondary;
Injections, Intraperitoneal;
Kidney Failure, Chronic;
Korea;
Parathyroid Hormone;
Parathyroidectomy;
Peritoneal Dialysis, Continuous Ambulatory;
Renal Dialysis
- From:Korean Journal of Nephrology
2011;30(2):206-210
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Secondary hyperparathyroidism is a major complication in ESRD patients undergoing dialysis. In hemodialysis patients with secondary hyperparathyroidism, intravenous administration of paricalcitol became widely utilized. In CAPD patients, however, the intravenous administration of paricalcitol which requires frequent visits to the clinic is not practical. The subject of this study was one CAPD patient with secondary hyperparathyroidism. He had already received oral calcitriol pulse therapy for 6 months and thereafter refused parathyroidectomy and intravenous paricalcitol which required frequent visits to the hospital. Furthermore, paricalcitol capsule is not yet introduced in Korea. Consequently, intraperitoneal paricalcitol therapy was tried whereby the patient was taught how to inject the paricalcitol (5 ug) directly into the dialysate for three times per week before bedtime. Blood samples for measurement of intact parathyroid hormone (iPTH), serum ionized calcium, serum phosphate, serum total alkaline phosphatase levels were obtained at baseline and after 1, 2, 3 and 4 months of treatment. After usage of intraperitoneal paricalcitol for 2 months, there was a significant decrease in iPTH level. In conclusion, intraperitoneal paricalcitol therapy might be effective for suppressing iPTH in CAPD patients with secondary hyperparathyroidism. A large-scale and long-term study must be conducted for safety and clinical effect.
